Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

SCINAI Aktie

 >SCINAI Aktienkurs 
0.515 EUR    (TradegateBSX)
Ask: 0.525 EUR / 3800 Stück
Bid: 0.505 EUR / 4000 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SCINAI Aktie über LYNX handeln
>SCINAI Performance
1 Woche: -5,5%
1 Monat: -27,0%
3 Monate: -18,6%
6 Monate: -55,2%
1 Jahr: -79,5%
laufendes Jahr: -5,5%
>SCINAI Aktie
Name:  SCINAI IMMUNOTHERAPEUTICS ADR
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09073Q3039 / A40DEH
Symbol/ Ticker:  2F5 (Frankfurt) / SCNI (NASDAQ)
Kürzel:  FRA:2F5, ETR:2F5, 2F5:GR, NASDAQ:SCNI
Index:  -
Webseite:  https://www.scinai.com/
Profil:  Scinai Immunotherapeutics Ltd is a biotechnology company engaged in the development of innovative immunotherapy solutions. The primary focus of Scinai Immunotherapeutics is to harness the power of the body's immune system to treat and potentially cur..
>Volltext..
Marktkapitalisierung:  0.47 Mio. EUR
Unternehmenswert:  -2.13 Mio. EUR
Umsatz:  1.09 Mio. EUR
EBITDA:  -
Nettogewinn:  -7.4 Mio. EUR
Gewinn je Aktie:  -10.63 EUR
Schulden:  -
Liquide Mittel:  2.6 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  -
Umsatzwachstum:  178.82%
Gewinnwachstum:  -335.18%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  SCINAI
Letzte Datenerhebung:  05.04.26
>SCINAI Kennzahlen
Aktien/ Unternehmen:
Aktien: 0.85 Mio. St.
Frei handelbar: 97.75%
Rückkaufquote: -
Mitarbeiter: 31
Umsatz/Mitarb.: 0.02 Mio. EUR
Analysten:
Analystenrating: No rating
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -679.01%
Operative Marge: -394.73%
Managementeffizenz:
Gesamtkaprendite: -
Eigenkaprendite: -
>SCINAI Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
02.04.26 - 08:42
 Scinai Immunotherapeutics reports FY results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 13:39
 Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration (PR Newswire)
 
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and......
19.03.26 - 12:54
 Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 (PR Newswire)
 
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and......
16.03.26 - 21:21
 Scinai Immunotherapeutics receives Nasdaq notice over minimum bid price requirement (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.03.26 - 21:09
 Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price (PR Newswire)
 
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance......
02.03.26 - 15:24
 Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept (PR Newswire)
 
JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under......
25.02.26 - 14:15
 Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform (PR Newswire)
 
JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been......
17.02.26 - 13:01
 Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm (PR Newswire)
 
JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of......
07.01.26 - 13:01
 Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL (PR Newswire)
 
JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief......
02.12.25 - 14:54
 Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances (PR Newswire)
 
JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its......
06.10.25 - 13:33
 Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities (PR Newswire)
 
Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad JERUSALEM, Oct. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics......
02.09.25 - 13:33
 Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet (PR Newswire)
 
JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases......
29.07.25 - 13:18
 Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN (PR Newswire)
 
New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM, July 29, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and......
26.06.25 - 13:39
 Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" (PR Newswire)
 
Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing......
05.06.25 - 15:03
 Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. (PR Newswire)
 
The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM, June 5, 2025......
30.05.25 - 16:00
 Scinai Immunotherapeutics reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.05.25 - 13:01
 Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn (PR Newswire)
 
JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases......
07.05.25 - 22:03
 Scinai Announces Annual Financial Results for 2024 (PR Newswire)
 
JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and......
01.05.25 - 13:00
 Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases (PR Newswire)
 
The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel, May 1, 2025 /PRNewswire/ -- Scinai......
27.03.25 - 14:30
 Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions (PR Newswire)
 
Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!